www.texasequineva.com • 29
BRIEF SUMMARY: Prior to use please consult the product insert, a summary of which follows: CAUTION: Federal law restricts this drug to use by or on the
order of a licensed veterinarian. INDICATIONS: Adequan
®
i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic
joint dysfunction and associated lameness of the carpal and hock joints in horses. CONTRAINDICATIONS: There are no known contraindications to the use of
intramuscular Polysulfated Glycosaminoglycan. WARNINGS: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all
medications out of the reach of children. PRECAUTIONS: The safe use of Adequan
®
i.m. in horses used for breeding purposes, during pregnancy, or in lactating
mares has not been evaluated. For customer care, or to obtain product information, visit www.adequan.com. To report an adverse event please contact American
Regent, Inc. at (800) 734-9236 or email pv@americanregent.com.
Please see Full Prescribing Information at
www.adequan.com.
Over the past 30 years, Adequan
®
i.m. (polysulfated glycosaminoglycan) has been recommended
millions of times
1
to treat degenerative disease, and with good reason. From day one, it's been
the only FDA-Approved equine PSGAG joint precription available, and the only one proven to.
2, 3
Restore synovial joint lubrication
Repair joint cartilage
Reverse the disease cycle
Reduce infl ammation
When you start with it early and stay with it as needed, horses may enjoy greater mobility
over a lifetime.
2, 4, 5
Discover if Adequan is the right choice. Talk to your American Regent
Animal Health sales representative or call (800) 458-0163 to order.
There's nothing else like it.
1 Data on fi le.
2 Adequan
®
i.m. Package Insert, Rev 1/19.
3 Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated
glycosaminoglycan in equine body fl uid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.
4 Kim DY, Taylor HW, Moore RM, Paulsen DB, Cho DY. Articular chondrocyte apoptosis in equine osteoarthritis. The Veterinary Journal 2003; 166: 52-57.
5 McIlwraith CW, Frisbie DD, Kawcak CE, van Weeren PR. Joint Disease in the Horse.St. Louis, MO: Elsevier, 2016; 33-48.
Adequan and the Horse Head design are registered trademarks of American Regent, Inc.
© 2019, American Regent, Inc. PP-AI-US-0222 2/2019
